X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Basilea gains a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 15, 2024
Details:
The financing will be used to fund the upcoming Phase 3 studies of ColiFin (colistimethate sodium), an inhaled antibiotic therapeutic for the management of chronic infections in cystic fibrosis patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Financing August 15, 2023
Details:
The net proceeds from the capital commitment will enable the initiation of the Phase 3 COPILOT study, the first part of the registrational clinical studies planned for ColiFin, an inhaled therapeutic for the management of chronic infections in cystic fibrosis patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 18, 2023
Details:
This collaboration is expected to provide capitalization through significant clinical milestones in ColiFin®’s Phase 3 development. ColiFin® (colistimethate sodium) is being developed for the treatment of chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 08, 2023
Details:
Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ultimately, cell death.
Lead Product(s): Murepavadin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Balixafortide (POL6326), is a potent, specific and highly selective macrocycle inhibitor of CXCR4 that plays a role in a number of tumor types as well as non-oncology indications.
Lead Product(s): Balixafortide,Undisclosed
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
In this trial, POL6326 (balixafortide) was shown to be safe and well tolerated in all subjects, with only transient and mild-to-moderate manageable hypersensitivity-like events known to occur during initial drug infusion with CXCR4 inhibitors.
Lead Product(s): Balixafortide
Therapeutic Area: Nephrology Product Name: POL6326
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
The preclinical study of metastatic prostate cancer combining POL6326 (balixafortide) and docetaxel (5 mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation. Overall, results showed superior synergistic efficacy compared to either drug alone.
Lead Product(s): Balixafortide,Docetaxel
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
The award will support the continuation of the "thanatin derivatives program" including POL7306, belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic class of antibiotics to potentially treat life-threatening infections.
Lead Product(s): POL7306
Therapeutic Area: Infections and Infectious Diseases Product Name: POL7306
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Funding March 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
